MetLife Investment Management’s AnaptysBio ANAB Stock Holding History

MetLife Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$564K	Sell	10,173 -154	-1%	-$8.29K	﹤0.01%	1691
2025 Q4	$501K	Sell	10,327 -1,601	-13%	-$62.4K	﹤0.01%	1790
2025 Q3	$365K	Buy	+11,928	New	+$274K	﹤0.01%	1964
2025 Q2	–	Sell	-11,928	Closed	-$222K	–	2785
2025 Q1	$222K	Sell	11,928 -326	-3%	-$5.44K	﹤0.01%	2143
2024 Q4	$162K	Hold	12,254	–	–	﹤0.01%	2405
2024 Q3	$411K	Hold	12,254	–	–	﹤0.01%	1886
2024 Q2	$307K	Buy	12,254 +1,211	+11%	+$28.2K	﹤0.01%	1987
2024 Q1	$249K	Hold	11,043	–	–	﹤0.01%	2072
2023 Q4	$237K	Hold	11,043	–	–	﹤0.01%	2146
2023 Q3	$198K	Hold	11,043	–	–	﹤0.01%	2214
2023 Q2	$225K	Hold	11,043	–	–	﹤0.01%	2196
2023 Q1	$240K	Hold	11,043	–	–	﹤0.01%	2108
2022 Q4	$342K	Hold	11,043	–	–	﹤0.01%	1882
2022 Q3	$282K	Hold	11,043	–	–	﹤0.01%	2067
2022 Q2	$224K	Hold	11,043	–	–	﹤0.01%	2240
2022 Q1	$273K	Buy	11,043 +4,009	+57%	+$121K	﹤0.01%	2152
2021 Q4	$244K	Hold	7,034	–	–	﹤0.01%	1935
2021 Q3	$191K	Sell	7,034 -4,237	-38%	-$108K	﹤0.01%	2123
2021 Q2	$292K	Hold	11,271	–	–	﹤0.01%	1910
2021 Q1	$243K	Hold	11,271	–	–	﹤0.01%	1947
2020 Q4	$242K	Hold	11,271	–	–	﹤0.01%	1870
2020 Q3	$166K	Hold	11,271	–	–	﹤0.01%	1973
2020 Q2	$252K	Hold	11,271	–	–	﹤0.01%	1762
2020 Q1	$159K	Hold	11,271	–	–	﹤0.01%	1816
2019 Q4	$183K	Hold	11,271	–	–	﹤0.01%	2023
2019 Q3	$394K	Hold	11,271	–	–	﹤0.01%	1552
2019 Q2	$636K	Buy	11,271 +1,789	+19%	+$129K	0.01%	1343
2019 Q1	$693K	Hold	9,482	–	–	0.01%	1256
2018 Q4	$605K	Buy	9,482 +1,243	+15%	+$92.4K	0.01%	1251
2018 Q3	$822K	Hold	8,239	–	–	0.01%	1228
2018 Q2	$585K	Hold	8,239	–	–	0.01%	1315
2018 Q1	$858K	Hold	8,239	–	–	0.01%	1071
2017 Q4	$830K	Buy	+8,239	New	+$607K	0.01%	1115

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MetLife Investment Management's ANAB Position: Q1 2026 in Review

MetLife Investment Management reduced its AnaptysBio (ANAB) stake by 1.5% in Q1 2026, selling an estimated $8.29K and leaving 10,173 shares worth $564K. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

MetLife Investment Management first reported a position in ANAB in Q4 2017 and has held it in 33 quarters since. The position peaked at $858K in Q1 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

MetLife Investment Management held 10,173 shares of AnaptysBio worth $564K as of Q1 2026.
MetLife Investment Management sold 154 AnaptysBio shares in Q1 2026, an estimated $8.29K.
AnaptysBio made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1691 holding.
MetLife Investment Management first reported a position in AnaptysBio in Q4 2017 and has held it in 33 quarters since.
MetLife Investment Management's AnaptysBio position peaked at $858K in Q1 2018.
207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.